Australia Age Related Macular Degeneration Market Size & Outlook
Australia age related macular degeneration market, 2017-2030 (US$M)
Related Markets
Australia age related macular degeneration market highlights
- The Australia age related macular degeneration market generated a revenue of USD 177.5 million in 2021 and is expected to reach USD 400.5 million by 2030.
- The Australia market is expected to grow at a CAGR of 9.5% from 2022 to 2030.
- In terms of segment, eylea was the largest revenue generating product in 2021.
- Beovu is the most lucrative product segment registering the fastest growth during the forecast period.
Age related macular degeneration market data book summary
| Market revenue in 2021 | USD 177.5 million |
| Market revenue in 2030 | USD 400.5 million |
| Growth rate | 9.5% (CAGR from 2021 to 2030) |
| Largest segment | Eylea |
| Fastest growing segment | Beovu |
| Historical data | 2017 - 2020 |
| Base year | 2021 |
| Forecast period | 2022 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Eylea, Lucentis, Beovu |
| Key market players worldwide | Roche Holding AG ADR, Novartis AG ADR, Bayer AG, Pfizer Inc, Bausch Health Companies Inc, Regeneron Pharmaceuticals Inc, Amgen Inc, Biogen Inc, Samsung Bioepis |
Other key industry trends
- In terms of revenue, Australia accounted for 1.8% of the global age related macular degeneration market in 2021.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Asia Pacific, Japan age related macular degeneration market is projected to lead the regional market in terms of revenue in 2030.
- Australia is the fastest growing regional market in Asia Pacific and is projected to reach USD 400.5 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Age Related Macular Degeneration Market Scope
Age Related Macular Degeneration Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Australia age related macular degeneration market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to age related macular degeneration market will help companies and investors design strategic landscapes.
Eylea was the largest segment with a revenue share of 53.8% in 2021. Horizon Databook has segmented the Australia age related macular degeneration market based on eylea, lucentis, beovu covering the revenue growth of each sub-segment from 2017 to 2030.
- Australia Age Related Macular Degeneration Product Outlook (Revenue, USD Million, 2017-2030)
- Eylea
- Lucentis
- Beovu
- Others
- Australia Age Related Macular Degeneration Disease Type Outlook (Revenue, USD Million, 2017-2030)
- Wet Age-related Macular Degeneration
- Dry Age-related Macular Degeneration
Reasons to subscribe to Australia age related macular degeneration market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Australia age related macular degeneration market databook
-
Our clientele includes a mix of age related macular degeneration market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Australia age related macular degeneration market , including forecasts for subscribers. This country databook contains high-level insights into Australia age related macular degeneration market from 2017 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Australia age related macular degeneration market size, by product, 2017-2030 (US$M)
Australia Age Related Macular Degeneration Market Outlook Share, 2021 & 2030 (US$M)
Related industry reports
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
